Milestone Pharmaceuticals Inc. (MIST)
NASDAQ$2.03
Market Cap
$108.26M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
709 of 924
Rank in Industry
404 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
MIST Insider Trading Activity
MIST Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil …
Insider Activity of Milestone Pharmaceuticals Inc.
Over the last 12 months, insiders at Milestone Pharmaceuticals Inc. have bought $0 and sold $0 worth of Milestone Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Milestone Pharmaceuticals Inc. have bought $7.01M and sold $8.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,000 shares for transaction amount of $32,830 was made by Bharucha David (Chief Medical Officer) on 2022‑12‑05.
List of Insider Buy and Sell Transactions, Milestone Pharmaceuticals Inc.
| 2022-12-05 | Bharucha David | Chief Medical Officer | 7,000 0.0162% | $4.69 | $32,830 | -27.58% | ||
| 2022-12-01 | Bharucha David | Chief Medical Officer | 3,000 0.007% | $4.86 | $14,580 | -29.01% | ||
| 2022-10-21 | Liebert Debra K. | director | 4,000 0.0096% | $5.26 | $21,040 | -28.77% | ||
| 2022-10-20 | Pasternak Richard C | director | 10,000 0.0232% | $5.20 | $52,000 | -30.21% | ||
| 2022-10-20 | Liebert Debra K. | director | 10,000 0.0236% | $5.29 | $52,900 | -30.21% | ||
| 2022-10-19 | Wills Robert James | director | 15,000 0.0349% | $4.93 | $73,950 | -26.41% | ||
| 2022-10-19 | TOMSICEK MICHAEL JOHN | director | 15,000 0.0376% | $5.32 | $79,800 | -26.41% | ||
| 2022-09-07 | Sale | WONG RODERICK | 1.56M 3.6651% | $8.71 | $13.56M | -56.03% | ||
| 2022-09-07 | WONG RODERICK | 1.56M 3.6651% | $8.71 | $13.56M | -56.03% | |||
| 2022-05-31 | TRUEX PAUL F | 5,000 0.0118% | $5.60 | $28,000 | -19.25% | |||
| 2020-07-29 | Sale | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10 percent owner | 500,000 1.5968% | $8.32 | $4.16M | -22.80% | |
| 2020-07-28 | Sale | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10 percent owner | 19,863 0.0675% | $8.10 | $160,890 | -15.61% | |
| 2020-03-19 | RTW INVESTMENTS, LP | 10 percent owner | 5,870 0.02% | $10.87 | $63,804 | -47.34% | ||
| 2020-03-18 | RTW INVESTMENTS, LP | 10 percent owner | 2,705 0.0091% | $10.36 | $28,029 | -45.49% | ||
| 2020-03-02 | RTW INVESTMENTS, LP | 10 percent owner | 78,263 0.3217% | $18.95 | $1.48M | -63.55% | ||
| 2020-01-13 | RTW INVESTMENTS, LP | 10 percent owner | 270,000 1.0575% | $16.25 | $4.39M | -59.47% | ||
| 2019-12-31 | RTW INVESTMENTS, LP | director | 21,438 0.0846% | $15.50 | $332,340 | -56.84% | ||
| 2019-12-30 | RTW INVESTMENTS, LP | director | 1,333 0.0054% | $15.48 | $20,638 | -55.51% | ||
| 2019-11-25 | Sale | Novo Holdings A/S | 10 percent owner | 240,000 0.8778% | $16.00 | $3.84M | -57.86% | |
| 2019-11-20 | RTW INVESTMENTS, LP | 10 percent owner | 400,000 1.4001% | $16.00 | $6.4M | -58.59% |
Total: 29
Insider Historical Profitability
<0.0001%
| RTW INVESTMENTS, LP | 10 percent owner | 4315102 8.0916% | $8.76M | 13 | 0 | |
| WONG RODERICK | 4315102 8.0916% | $8.76M | 1 | 1 | <0.0001% | |
| Novo Holdings A/S | 10 percent owner | 2434470 4.5651% | $4.94M | 1 | 1 | |
| BDC CAPITAL INC. | 10 percent owner | 2388088 4.4781% | $4.85M | 1 | 0 | |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10 percent owner | 2254920 4.2284% | $4.58M | 1 | 2 |
Historical Insider Profitability vs. Competitors
$12,784,645 | 193 | 20.49% | $110.08M | |
$22,597,521 | 91 | 4.59% | $109.66M | |
$54,751,750 | 62 | -1.03% | $114.62M | |
$16,245,616 | 40 | 123.58% | $117.65M | |
$36,079,815 | 31 | 43.23% | $100.89M |
MIST Institutional Investors: Active Positions
| Increased Positions | 24 | +48% | 2M | +6.32% |
| Decreased Positions | 20 | -40% | 6M | -19.62% |
| New Positions | 10 | New | 1M | New |
| Sold Out Positions | 6 | Sold Out | 510,350 | Sold Out |
| Total Postitions | 54 | +8% | 25M | -13.31% |
MIST Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $6,603.00 | 7.64% | 4.05M | -920,658 | -18.52% | 2024-12-31 |
| Millennium Management Llc | $4,406.00 | 5.1% | 2.7M | -75,266 | -2.71% | 2024-12-31 |
| Alta Fundamental Advisers Llc | $4,334.00 | 5.02% | 2.66M | 0 | 0% | 2024-12-31 |
| Rtw Investments, Lp | $4,085.00 | 4.73% | 2.51M | -750,000 | -23.03% | 2024-12-31 |
| Orbimed Advisors Llc | $3,260.00 | 3.77% | 2M | 0 | 0% | 2024-12-31 |
| Nantahala Capital Management, Llc | $2,356.00 | 2.73% | 1.45M | -304,736 | -17.41% | 2024-12-31 |
| Bleichroeder Lp | $2,162.00 | 2.5% | 1.33M | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $2,101.00 | 2.43% | 1.29M | +370,829 | +40.38% | 2024-12-31 |
| Bml Capital Management, Llc | $1,852.00 | 2.14% | 1.14M | 0 | 0% | 2024-12-31 |
| Lion Point Capital, Lp | $1,672.00 | 1.94% | 1.03M | -628,348 | -37.99% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.